NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance. The cost-effectiveness body said
NICE has recommended NHS funding for Roche’s Rozlytrek (entrectinib) as a treatment option for advanced non-small cell lung cancer with a rare mutation in
NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell
NICE has recommended regular NHS funding for Roche’s immunotherapy Tecentriq (atezolizumab) in tough-to-treat advanced triple negative breast cancer in final draft guidance, after a previous rejection. The
